Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
| Autor: | Jin Li, Johan M. Kros, Ping Pin Zheng |
|---|---|
| Přispěvatelé: | Pathology |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty T cell Lymphoblastic Leukemia Antigens CD19 Receptors Antigen T-Cell 03 medical and health sciences hemic and lymphatic diseases Internal medicine Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Drug Discovery medicine Humans Young adult B-cell lymphoma B cell Pharmacology Adult patients business.industry medicine.disease Chimeric antigen receptor 030104 developmental biology medicine.anatomical_structure Treatment Outcome Drug Resistance Neoplasm Quality of Life Car t cells business |
| Zdroj: | Drug Discovery Today, 23(6), 1175-1182. Elsevier Ltd. |
| ISSN: | 1359-6446 |
| Popis: | Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah™ and Yescarta™) were recently approved by the FDA. Kymriah™ is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia and Yescarta™ is for the treatment of adult patients with R/R large B cell lymphoma. In common, both are CD19-specific CAR T cell therapies lysing CD19-positive targets. Their dramatic efficacy in the short term has been highlighted by many media reports. By contrast, their glaring safety gaps behind the miracles remain much less addressed. Here, we focus on addressing the crucial challenges in relation to the gaps. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect